

Guide for clinical case management and infection prevention and control during a measles outbreak



Guide for clinical case management and infection prevention and control during a measles outbreak

ISBN 978-92-4-000286-9 (electronic version) ISBN 978-92-4-000287-6 (print version)

### © World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Guide for clinical case management and infection prevention and control during a measles outbreak. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by L'IV Com Sàrl

Printed in Switzerland

# Contents

| Ackno   | Acknowledgements   |          |  |  |  |
|---------|--|----------|--|--|--|
| Abbre   | viations   | <b>v</b> |  |  |  |
| 1. Intr | oduction   | 1        |  |  |  |
|         | Target audience  |          |  |  |  |
|         | Key recommendations  |          |  |  |  |
| 2. Obj  | ectives  | 3        |  |  |  |
| 3. Bac  | kground  | Z        |  |  |  |
| 3.1     | Disease  | Z        |  |  |  |
| 3.2     | Clinical presentation  | Z        |  |  |  |
| 3.3     | Complications  | 4        |  |  |  |
| 4. Pub  | lic health surveillance case definitions and classifications                             | 5        |  |  |  |
| 5. Clin | ical management and infection prevention and control measures                            | 7        |  |  |  |
| 5.1     | Early recognition/triage of patients with clinically suspected measles or severe illness | 8        |  |  |  |
| 5.2     | Early infection prevention and control: apply standard and airborne precautions          | 9        |  |  |  |
| 5.3     | Immediate administration of vitamin A  | 11       |  |  |  |
|         | Symptomatic treatments for prevention of complications                                   |          |  |  |  |
| 5.5     | Early supportive care for sepsis/severe illness  | 13       |  |  |  |
| 6. Mar  | naging measles exposures   | 19       |  |  |  |
| 6.1     | Health care workers  | 19       |  |  |  |
| 6.2     | Patients   | 19       |  |  |  |
| Refere  | ences  | 20       |  |  |  |
| Annex   | 1. Key criteria to assess nutrition and vital signs in children                          | 22       |  |  |  |
|         | 2. Classification of dehydration   |          |  |  |  |
| AIIIIUX | . Z. Classification of utilival ation  |          |  |  |  |

## Acknowledgements

This document was developed by the Essential Programme on Immunization (EPI) Unit of the Department of Immunization, Vaccines and Biologicals (IVB) of the World Health Organization (WHO). The following individuals have contributed to the production of the guide and their inputs are acknowledged with sincere gratitude.

#### Expert panel

Dale Fisher (co-chair, Global Outbreak Alert and Response Network [GOARN] chair); Srinivas Murthy (co-chair, University of British Columbia, Canada); Kulkanya Chokephaibulkit (Mahidol University, Thailand); Dianne Crellin (University of Melbourne, Australia); Vu Quoc Dat (Hanoi Medical University, Viet Nam); Nicola Gini (Starship Children's Hospital, Auckland, New Zealand); Timothy Gray (Concord Repatriation General Hospital, New South Wales, Australia); Richard Kojan (The Alliance for International Medical Action [ALIMA], Senegal); Hans-Joerg Lang (University of Witten/Herdecke, Germany); Paula Lister (Sunshine Coast University Hospital, Australia); Peter Prager (University of Queensland, Australia); Helena Rabie (Stellenbosch University, South Africa); Naoki Shimizu (St Marianna University School of Medicine, Japan).

Note: All members of the expert panel completed conflict of interest forms and none reported a conflict of interest.

Médecins Sans Frontières: Tanja Ducomble.

United Nations Children's Fund: Maria Otelia Costales, Imran Mirza, Yodit Sahlemariam.

United States Centers for Disease Control and Prevention: Jeffrey McFarland, Mark Papania, Robert Perry.

**WHO:** April Baller, Diana Chang Blanc, Janet Diaz, Santosh Gurung, Jose Hagan, Lee Lee Ho, Dragan Jankovic, Sudhir Khanal, Katrina Kretsinger, Margaret Lamunu, Ann Lindstrand, Laura Nic Lochlainn, Balcha Girma Masresha, Mick Mulders, Susan Norris, Katherine O'Brien, Maria Clara Padoveze, Desiree Pastor, Minal Patel, Lisa Rogers, Alex Rosewell, Wilson Milton Were, Nasrin Musa Widaa.

### **Abbreviations**

AIIR airborne infection isolation room

ARDS acute respiratory distress syndrome

BP blood pressure

**bpm** beats per minute

CLIA Clinical Laboratory Improvement Amendments

**CPAP** continuous positive airway pressure

CRT capillary refill time

**HCW** health care worker

HEPA high-efficiency particulate air

HIV human immunodeficiency virus

HR heart rate

IO intraosseous

IPC infection prevention and control

ISO International Organization for Standardization

IV intravenous

NS normal saline

ORS oral rehydration salts

PEP post-exposure prophylaxis

PPE personal protective equipment

RL Ringer's lactate

RR respiratory rate

SOP standard operating procedure

SpO<sub>2</sub> peripheral oxygen saturation

**SSPE** subacute sclerosing pan encephalitis

WHO World Health Organization



https://www.yunbaogao.cn/report/index/report?reportId=5\_24739

